

Review of: "First long-term safety analysis of the ChAdOx1-nCoV-19 corona virus vaccine: results from a prospective observational study in priority vaccinated groups in North India"

Adekunle Sanyaolu

Potential competing interests: No potential competing interests to declare.

This was a prospective observational study which was conducted from February 2021 to April 2022 in a tertiary hospital of North India and its two associated centers. The study provided a one-year safety results of the ChAdOx1-nCoV-19/AZD1222 vaccine by investigating the risk factors of development of adverse events of special interest (AESIs) as well as persistent AESIs. The study is well conducted by the authors and provide a good literature on the long term adverse events of special interest regarding the Covishield vaccine. I only have few minor comments. The study would be enriched by comparing the result with studies on other Covid 19 vaccine. Also, the explanation provided in the discussion for low reporting rate of AESIs may not be accurate but rather can be ascribe to the urgency in demand for a vaccine to control the Covid 19 pandemic which might have not provided enough time to study the vaccine before approval, hence the need for a EUA. The study will be enriched with these studies:

Sanyaolu A, Marinkovic A, Prakash S, Desai P, Haider N, Abbasi AF, Mehraban N, Jain I, Ekeh A, Shazley O, Okorie C. Reactogenicity to COVID-19 vaccination in the United States of America. *Clinical and Experimental Vaccine Research*. 2022 Jan;11(1):104.

Rosenblum HG, Hadler SC, Moulia D, Shimabukuro TT, Su JR, Tepper NK, Ess KC, Woo EJ, Mba-Jonas A, Alimchandani M, Nair N. Use of COVID-19 vaccines after reports of adverse events among adult recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 vaccines (Pfizer-BioNTech and Moderna): update from the Advisory Committee on Immunization Practices—United States, July 2021. *Morbidity and Mortality Weekly Report*. 2021 Aug 8;70(32):1094.

Gee J, Marquez P, Su J, Calvert GM, Liu R, Myers T, Nair N, Martin S, Clark T, Markowitz L, Lindsey N. First month of COVID-19 vaccine safety monitoring—United States, December 14, 2020–January 13, 2021. *Morbidity and mortality weekly report*. 2021 Feb 2;70(8):283.

Singh A, Khillan R, Mishra Y, Khurana S. The safety profile of COVID-19 vaccinations in the United States. *American journal of infection control*. 2022 Jan 1;50(1):15-9.

Montano D. Frequency and associations of adverse reactions of COVID-19 vaccines reported to pharmacovigilance systems in the European Union and the United States. *Frontiers in public health*. 2022:2237.

Montano D. Frequency and associations of adverse reactions of COVID-19 vaccines reported to pharmacovigilance systems in the European Union and the United States. *Frontiers in public health*. 2022:2237.